ATOS Atossa Therapeutics Inc

Price (delayed)

$2.56

Market cap

$25.55M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$4.45

Enterprise value

-$656,997

?
Relative Growth: Rel. Growth: 4
Relative Strength: Rel. Strength: 2
Relative Valuation: Rel. Valuation: N/A
Relative Profitability: Rel. Profitability: 2

Atossa Genetics Inc. is a clinical-stage biopharmaceutical company developing novel therapeutics and delivery methods to treat breast cancer and other breast conditions.

Highlights
The quick ratio has declined by 43% year-on-year but it has grown by 13% since the previous quarter
The company's equity has shrunk by 53% YoY and by 12% QoQ
The net income has contracted by 31% YoY

Key stats

What are the main financial stats of ATOS

ATOS stock price

How has the Atossa Therapeutics stock price performed over time
Intraday
8.94%
1 week
5.79%
1 month
6.67%
1 year
-78.29%
YTD
-71.07%
QTD
32.64%

Financial performance

How have Atossa Therapeutics's revenue and profit performed over time
Revenue
$0
Gross profit
$0
Operating income
-$39.25M
Net income
-$37.71M
Gross margin
N/A
Net margin
N/A
The net income has contracted by 31% YoY
The operating income fell by 31% YoY

Price vs fundamentals

How does ATOS's price correlate with its fundamentals

Growth

What is Atossa Therapeutics's growth rate over time

Valuation

What is Atossa Therapeutics stock price valuation
P/E
N/A
P/B
0.82
P/S
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
The company's EPS fell by 29% YoY
The company's equity has shrunk by 53% YoY and by 12% QoQ
ATOS's P/B is 49% below its last 4 quarters average of 1.6 and 45% below its 5-year quarterly average of 1.5

Efficiency

How efficient is Atossa Therapeutics business performance
The return on equity has dropped by 141% year-on-year and by 21% since the previous quarter
The ROA has plunged by 117% YoY and by 19% from the previous quarter

Dividends

What is ATOS's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for ATOS.

Financial health

How did Atossa Therapeutics financials performed over time
The company's total assets fell by 50% YoY and by 15% QoQ
The quick ratio has declined by 43% year-on-year but it has grown by 13% since the previous quarter
ATOS's debt is 100% smaller than its equity
The company's equity has shrunk by 53% YoY and by 12% QoQ

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.